Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Up-regulation of miR-934 serves as an independent prognostic factor for lung cancer and promotes proliferation, migration and invasion of non-small cell lung cancer cells.

Journal of biological regulators and homeostatic agents·2021

Same author

Observation and Measurement of Forward Proton Scattering in Association with Lepton Pairs Produced via the Photon Fusion Mechanism at ATLAS.

Physical review letters·2021

Same author

Search for Heavy Resonances Decaying into a Photon and a Hadronically Decaying Higgs Boson in pp Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Physical review letters·2021

Same author

Search for Higgs Boson Decays into a Z Boson and a Light Hadronically Decaying Resonance Using 13 TeV pp Collision Data from the ATLAS Detector.

Physical review letters·2020

Same author

The effect of <i>Clostridium tyrobutyricum Spo0A</i> overexpression in the intestine of mice.

Beneficial microbes·2020

Same author

Dijet Resonance Search with Weak Supervision Using sqrt[s]=13 TeV pp Collisions in the ATLAS Detector.

Physical review letters·2020

Search research articles

Related Experiment Video

Updated: May 7, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

A causal role for circulating miR-34b in osteosarcoma.

Q Tian¹, J Jia¹, S Ling¹

¹Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.

European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

|September 26, 2013

Summary

Plasma miR-34b levels are significantly lower in osteosarcoma (OS) patients and are causally linked to OS risk. This suggests plasma miR-34b may serve as a novel biomarker for OS and its metastatic status.

Keywords:

Osteosarcoma SNPs miRNA-34b

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Related Experiment Videos

Last Updated: May 7, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

Area of Science:

Molecular Biology
Oncology
Genetics

Background:

Osteosarcoma (OS) is a primary bone malignancy with significant morbidity.
MicroRNAs (miRNAs) play crucial roles in tumorigenesis and cancer progression.
The role of miR-34b/c in OS pathogenesis requires further investigation.

Purpose of the Study:

To investigate the association between plasma miR-34b/c expression levels and osteosarcoma (OS).
To explore the potential of plasma miR-34b as a biomarker for OS.
To examine the relationship between miR-34b expression and OS metastatic status.

Main Methods:

A case-control study involving 133 OS patients and 133 controls.
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to measure plasma miR-34b/c levels.
TaqMan assay for genotyping of single nucleotide polymorphism (SNP) rs4938723.
Mendelian randomization analysis to assess causal associations.

Main Results:

Plasma miR-34b levels were significantly lower in OS patients compared to controls (P = 0.001).
Decreased miR-34b expression in OS tissues correlated with plasma levels (r = 0.21, P = 0.004).
SNP rs4938723 variant genotypes (TC/CC) were associated with increased OS risk and decreased plasma miR-34b levels.
Adjustment for miR-34b abolished the association between SNP rs4938723 and OS risk.
Plasma miR-34b levels were significantly lower in metastatic OS patients.

Conclusions:

Plasma miR-34b is causally associated with osteosarcoma risk.
Plasma miR-34b expression levels correlate with the metastatic status of OS.
Plasma miR-34b shows potential as a novel biomarker and therapeutic target for OS.